Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment.
Smith EA, Belote RL, Cruz NM, Moustafa TE, Becker CA, Jiang A, Alizada S, Prokofyeva A, Chan TY, Seasor TA, Balatico M, Cortes-Sanchez E, Lum DH, Hyngstrom JR, Zeng H, Deacon DC, Grossmann AH, White RM, Zangle TA, Judson-Torres RL.
Smith EA, et al.
J Exp Clin Cancer Res. 2024 Dec 3;43(1):317. doi: 10.1186/s13046-024-03234-1.
J Exp Clin Cancer Res. 2024.
PMID: 39627834
Free PMC article.